The vaccine of Sardinians against the coronavirus
By continuing to browse, clicking on ok or scrolling the page, you consent to the use of all cookies.
OkInformation on cookies
Coronavirus vaccine in September. The gamble of the Oxford researchers
The race to the vaccine against the new coronavirus does not stop. And indeed it accelerates, as many groups of scientists around the world are looking for ways to shorten the canonical times of experimentation of a vaccine, which generally lasts 2 or even 3 years. But a team from the Lenner Institute at Oxford University announced that a new vaccine under study may already be ready to September, hopefully, and available initially for a few million doses. To give news of the timing are the same researchers an article on New York Times, while information on the clinical trial on volunteers, which has just started, can be found on the page of the University of Oxford. The conditional is a must because the tests on volunteers have only now started and the study will have to confirm the positive outcome, in terms of safety and efficacy, already observed on animals in the previous phase of the experimentation.
Favorable outcome in animals
The experimental vaccine developed by the Oxford scientists worked well on monkeys. The vaccine was administered as a single dose to six specimens of macaque rhesus. The animals were then exposed to large concentrations and quantities of the new coronavirus, capable of infecting. After 28 days all the macaques were healthy and had no traces in tests for the presence of the virus. "This macaque is the closest animal we have to human beings", pointed out on the New York Times researcher Vincent Munster, which takes part in the experimentation. The expert reports that the group will publish the first results of the study, yet not peer reviewed, presumably in the first days of May.
The vaccine in question is composed of a virus (ChAdOx1 - hence the name of the vaccine) which is a weakened version of a common cold-causing virus, a adenovirus. To this was added the genetic material of the new coronavirus - the part that produces the protein spike, which Sars-Cov-2 uses to enter human cells and infect them, like a sort of hook that harpoons them. The goal is that with the vaccine the body begins to recognize the virus and the immune system produces a response against the spike protein that prevents the virus from penetrating into the cells.
The next steps
Now the researchers are about to start giving the vaccine to volunteers - it just got started clinical study - and between now and September they will be involved in the tests about 6 thousand people. The problem, if anything, explain the authors on New York Times, may relate to the fact that, if in the next period the epidemic will be completely contained - which we all hope - however, there will not be a sufficient number of people in places where the infection is circulating, eligible for vaccination for the test. Obviously, scientists hope that Covid-19 will disappear as soon as possible, in the coming weeks, however this would imply not being able to reach enough scientific evidence to be able to develop a vaccine. But there could also be other obstacles, so the road can be winding, even if we hope it won't be very long.
What if there was more than one vaccine?
Furthermore, this is certainly not the only vaccine studied and it may not be the only one that will arrive in the fight against the new coronavirus. But a possible plurality of options is not bad, as he explains Emilio Emini, among the directors of the Foundation's Vaccine Research Program Bill & Melinda Gates, which is supporting several coronavirus research projects. This is because each type of vaccine could be most effective on a certain category of people - based on risk and other characteristics.
Cover image credits: NIAID-RML via Flickr CC
The second Russian vaccine EpiVacCorona generates antibodies in 100% of cases and does not induce severe reactions
When it comes to Russian anti Covid vaccine basically it refers to the Sputnik V (Gam-COVID-Vac) of the Gamaleya Research Institute in Moscow, which in a recent study published in the prestigious journal The Lancet has been shown to have an efficacy of 91.6 percent. However the vaccination campaign in Russia can also count on two other drugs approved and produced at home: theEpiVacCorona, developed by scientists from the Federal Budget Research Institute - State Research Center of Virology and Biotechnology "Vector"(a maximum biosecurity laboratory) and the CoviVac, developed by the Federal Scientific Center for Research and Development of Immunobiology Drugs "Chumakov"of St. Petersburg. All three vaccines were approved by the Ministry of Health before having concluded the natural experimental process, and it is no coincidence that there was a long discussion on theeffective effectiveness of Sputnik V (which later proved to be largely valid).
Regarding theEpiVacCoronaAlthough it was registered in October 2020 and mass administration started in January, the results of one have only now been published clinical study subjected to peer review. Fortunately, the data is quite encouraging, although a small number of participants were involved. It was in fact a small one Phase 1-2 clinical study, in single blind, randomized is placebo controlled. In the first part of the survey, 14 volunteers between the ages of 18 and 30 were involved, while in the second, 86 participants between the ages of 18 and 60. It was led by the same scientists from Rospotrebnadzor's “Vector”, in close collaboration with colleagues from the satellite company LLC “EpiVac” and the Federal Medical and Biological Agency of Russia. As this is a Phase 1-2 study, the researchers led by professors R.A. Maksyutov and A.B. Ryzhikov analyzed safety, reactogenicity is immunological activity of the vaccine, given with two intramuscular injections, of which the second 21 days after the first (as happens with other COVID vaccines, for example that of Pfizer is BioNTech). From the analysis of the data it emerged that the drug induced the production of specific antibodies for the antigens that make up the vaccine (against protein S or Spike) in 100 percent of volunteers. “Seroconversion with a neutralizing antibody titer ≥ 1:20 was reported in 100 percent of the volunteers 21 days later,” reads the study abstract. Put simply, the vaccine appears to trigger one robust antibody response against the SARS-CoV-2 coronavirus.
in the picture: Vaccine-triggered antibodies. Credit: Vector / Infektsiya i immunitet
The results related to the tolerability of the drug. In fact, none of the patients involved emerged adverse reactions ed side effects severe. In Stage 1 young people only 2 experienced pain at the injection site, and there have been no cases of systemic symptoms such as headache, myalgia, asthenia and temperature. In the Phase 2 study, injection site pain was detected in a handful of volunteers after both the first and second injection, and only one developed a mild fever (which disappeared after 12 hours) followed by headache and ear pain (ear infection). There were no significant changes in body temperature (except in the case mentioned above), blood pressure, heart rate or respiratory rate of any volunteer. Put simply, the EpiVacCorona was found to be largely effective, but much more extensive and in-depth studies will be needed than Phase 3 (at the moment one is underway with 3 thousand participants) to understand how effective it really is. Because symptoms such as fever, headache, muscle aches and the like indicate that the vaccine is doing its duty and therefore working. As pointed out by the Wall Street Journal, a group of volunteers involved in clinical trials wrote a letter in which it was stated that the "vaccine did not generate a sufficient immune response". According to what Dr. Tatyana Nepomnyashchikh, director of Vector, previously declared to the Russian news agency TASS, the vaccine should guarantee protection against SARS-CoV-2 for one year.
EpiVacCorona is a vaccine a viral vector is recombinant proteins, peptide antigens synthesized from SARS-CoV-2 coronavirus proteins, as indicated in the presentation of the study "Study of the Safety, Reactogenicity and Immunogenicity of" EpiVacCorona "Vaccine for the Prevention of COVID-19 (EpiVacCorona)". The vaccine uses a adjuvant based on aluminum (aluminum hydroxide) to enhance theimmunogenic action. The first clinical data published in a scientific journal seem promising, but it is still too early to be sure of the actual efficacy, despite the antibody response observed in all participants. The details of the research "A single blind, placebo-controlled, randomized study of the safety, reactogenicity and immunogenicity of the 'EpicVacCorona' Vaccine for the Prevention of COVID-19, in voulunteers aged 18-60 years (Phase 1-2)" were published in the Russian scientific journal Infection and Immunity (Infektsiya i immunitet)
Usa, green light for Johnson & Johnson single-dose vaccine: "We can stop the coronavirus"
To increase production, the American company has partnered with Catalent, which is headquartered in New Jersey, from 2020. The agreement provides that part of the vaccine production will be made in the US and in Italy, in the Anagni plant of Catalent, in the province of Frosinone. Another agreement, for the five-year production of vaccines, has been signed with Emergent BioSolutions, whose plants are located in Maryland. The French pharmaceutical company Sanofi also offered J&J its Marcy l'Etoile plant for the production of the Janseen vaccine (J&J subsidiary) at a rate of 12 million doses per month. A fourth vaccine could come soon: Sanofi and GlaxoSmithKline have announced testing on 720 adults. If the response is encouraging, the first doses may be available from October.
Last Check Date: March 25, 2021
On March 15th, as a completely precautionary measure and following some rare cases of thromboembolic events, which occurred in some European countries, AIFA and the regulatory agencies of other EU countries recommended the temporary suspension of the use of the anti-inflammatory vaccine. COVID-19 AstraZeneca asking the European Medicines Agency (EMA) to evaluate the collected cases.
The few cases reported were mostly related to the diagnosis of cerebral venous thrombosis (CVST) accompanied in the majority of reports by concomitant platelet deficiency (thrombocytopenia) and bleeding. In Italy, according to AIFA data, out of over 1.1 million doses of the vaccine administered, only one adverse reaction of this type temporally related to the vaccine was detected.
In extended vaccination campaigns, it is common for countries to report potential adverse events.
On March 18, the EMA, after having thoroughly analyzed all the data with the support of experts in thromboembolic diseases, confirmed that the vaccine COVID-19 AstraZeneca, like the others authorized by EMA, it is a safe and effective vaccine and is not associated with an increased overall risk of thromboembolic disease in the general population.
EMA will conduct further analyzes to investigate the possible association of vaccination with very rare cases of blood clots associated with thrombocytopenia, i.e. low levels of platelets with or without bleeding, including rare cases of cerebral venous sinus thrombosis (CVST).
It is therefore confirmed that the benefits of the vaccine in combating COVID-19, a disease that itself causes clotting problems that can be fatal, continue to outweigh the risk of any side effects.
To know more
The goal of the population vaccination campaign is to prevent deaths from COVID-19 and to achieve herd immunity to SARS-CoV2 as soon as possible. The campaign started on December 27 in demonstrative form in Italy and Europe with the vaccine day and effectively on 31 December 2020, after approval by the EMA (European Medicines Agency) of the first COVID-19 vaccine. After an initial phase, which must be limited, due to the number of doses delivered, it will develop continuously increasing according to the Strategic Plan.
Vaccines are offered free to the entire population, according to an order of priority, which takes into account the risk of disease, the types of vaccines and their availability.
Italy, based on the agreements entered into, will be able to count on the availability of more 242 million doses (see Table).
- Vaccine Comirnaty of Pfizer-BioNtech - it is the first vaccine to be authorized in the European Union: on 21 December 2020 by the European Medicines Agency (EMA) and on 22 December by the Italian Medicines Agency (AIFA).
- Vaccine Modern - on 6 January it was authorized by the EMA and on 7 January by AIFA.
- Vaccine AstraZeneca - on 29 January it was authorized by the EMA and on 30 January by AIFA.
- Vaccine Janssen of Johnson & Johnson - it is the fourth vaccine authorized by the EMA on 11 March and by AIFA on 12 March 2021.
to know more
Yes. Vaccines are authorized only after a careful evaluation of the safety profile based on the studies carried out in the experimental phase.
In any case, the security profile is continuously monitored even after authorization.
- Health and social health workers - “Frontline” health and social health workers, both public and accredited private, have a higher risk of being exposed to COVID-19 infection and of transmitting it to susceptible and vulnerable patients in health and social settings. Furthermore, it is recognized that vaccination of frontline health and social health workers will help maintain the resilience of the health service.
- Residents and staff of residential care centers for the elderly - A high percentage of nursing homes (RSAs) have been severely affected by COVID-19. Residents of these facilities are at high risk of serious illness, due to their advanced age, the presence of multiple comorbidities and the need for assistance with eating and other daily activities.
- People of advanced age. An age-based vaccination program is generally easier to implement and allows for greater vaccination coverage. It is also evident that an age-based program increases coverage even in people with clinical risk factors, as the prevalence of comorbidities and disabilities increases with age. Therefore, given the high probability of developing a serious disease and the consequent recourse to intensive or sub-intensive care admissions, this population group represents a priority for vaccination.
With the updating of the recommendations on target populations for the vaccination campaign, the highest priority is expected for the new one macro-category of high fragility (Category 1), which includes:
- there category of the extremely vulnerable, or people suffering from specific conditions which, due to pre-existing organ damage or who due to an impairment of the immune response to SARS-CoV-2, present a particularly high risk of developing severe or lethal forms of Covid-19
- there category of people with severe disabilities, severely disabled pursuant to law 104/1992 art.3 paragraph 3, their cohabiting family members e caregiver who provide ongoing assistance.
Following are categories based on personal criteria and presence of pathologies, in order to favor a continuation of the campaign as quick and fair as possible in all Regions:
- Category 2: People aged between 70 and 79
- Category 3: People aged between 60 and 69 years
- Category 4: People with age comorbidities Will children be vaccinated?
Vaccines currently authorized in Italy and Europe are not currently recommended for children under the age of:
- 16 years (Comirnaty of Pfizer-BioNtech)
- 18 years (Modern, AstraZeneca is Janssen of Johnson & Johnson).
The European Agency (EMA), as well as other international agencies, await further studies in order to authorize vaccination on the pediatric population.
According to the Covid-19 vaccine plan, people with immunodeficiency or being treated with immunomodulating drugs will have to be vaccinated in the early stages, as they are more susceptible to getting Covid-19.
In subjects identified as extremely vulnerable, due to immunodeficiency conditions, primary or secondary to pharmacological treatments or to concomitant pathology, which considerably increases the risk of developing fatal forms of COVID-19, the indication for a preferential use of messenger RNA vaccines is confirmed (Modern and Pfitzer).
Yes, it is possible to administer a single dose of anti-SARSCoV-2 / COVID-19 vaccine in people who have already had SARS-CoV-2 infection, both symptomatically and asymptomatically, provided that the vaccination is performed at at least 3 months away from the documented infection and preferably within 6 months from the same.
Read the Ministerial Circular of March 3, 2021
Clinical studies on Comirnaty (Pfizer-BioNtech) is Modern have shown a very high efficacy of the vaccines, respectively, after one week and two weeks after the second dose.
Regarding Vaccine AstraZeneca clinical studies have shown maximum efficacy 15 days after the second dose.
The maximum protection is therefore obtained after the indicated periods.
Although even after the first dose there is likely to be some protection from the virus, this is not immediate after vaccine injection, but develops progressively at least 7-14 days after injection. The second dose of the vaccine, carried out at least 21 days from the first dose for Comirnaty, to 28 for Moderna and in the course of 12th week from the first dose for AstraZeneca, it has the task of reinforcing the protection and making it more prolonged.
Regarding the efficacy of the single-dose vaccine Janssen Covid-19 Vaccine (Johnson & Johnson), in severe forms it reaches up to 77% after 14 days of administration and 85% after 28 days of administration. Currently available data showed that no decline in efficacy was noted in subjects over 65.
For three vaccines authorized by EMA and AIFA (Comirnaty, Moderna, AstraZeneca) are provided two doses, a few weeks apart, based on the type of vaccine.
For people who have already had the infection, which has passed symptomatically or asymptomatically, it is possible to consider the administration of a single dose, provided that vaccination is carried out at least 3 months away from the infection and preferably within 6 months from the same.
The indication is not applicable to subjects with immunodeficiency, primary or secondary to pharmacological treatments, in which it is recommended to carry out two doses for the vaccines currently available, since the immunological protection conferred by the SARS-CoV-2 infection is not predictable. and its duration.
For the vaccine Janssen the administration of a single dose.
AIFA (Italian Medicines Agency), in addition to the pharmacovigilance activities normally provided for drugs and vaccines (based on spontaneous reports and on the pharmacovigilance networks already present), will promote the launch of some independent post-authorization studies on COVID vaccines. 19.
The supervisory activities will concern both the collection and evaluation of spontaneous reports of suspected adverse reactions (passive pharmacovigilance) and proactive actions, through pharmaco-epidemiology studies / projects (active pharmacovigilance). AIFA has a Scientific Committee, which, for the entire period of the vaccination campaign, will have the function of supporting the Agency and the scientific managers of the individual studies in the phase of setting up the activities, in the overall analysis of the data that will be collected and in the identification of possible interventions. The aim is to have, also through an international collaborative network, the ability to highlight any possible risk signals and, at the same time, to compare the safety profiles of the different vaccines that will become available, to provide recommendations.
Read also the Drug Safety page on the AIFA website.
A normal vaccination certificate will certainly be issued.
International institutions such as the European Commission and WHO are evaluating a proposal for an international digital certificate.
A dashboard where the data and statistics relating to the administration of vaccines throughout the national territory are collected.
Check out the dashboard
From 5 January 2021 the data of the dashboard Vaccine reports are also available in open to the page:
- Directorate General of Health Prevention
After the age of 80 and over 70, some regions have started to vaccinate against Covid-19 Even the people aged 70-71. Not all of them are in line, due to delays in the previous phases of the vaccination campaign, in supplies and then for the stop of the AstraZeneca vaccine for a few days (now restarted, after the new evaluation by Ema and the decision to restart Health).
We have collected the main indications and i region-by-region references.
Abruzzo continues the collection of expressions of interest to anti-Covid vaccination through their own online platform . From here you can access the pages reserved for teaching and non-teaching staff of Abruzzo schools and universities, to the personnel of the training centers accredited by the Abruzzo Region, to the personnel nursery schools public and private, to the health workers Phase I priority categories not included in the vaccination initiation phase, and ai over eighty . The portal has been updated at the moment with the category of people among 75 and i 79 years old .
The region, however, has also joined the booking platform of the Italian Post Office . Information can be found on this site .
Basilicata seems to have chosen a other way . It hasn't implemented an online booking platform, but the vaccination plan has been programmed by the region on the basis of chronological age of residents. No reservations needed, but interested citizens should be contacted by phone from the Cup or consult the vaccination calendars and present a document to the reference vaccination point. Now that the Italian Post Office platform , we can refer to this.
The Autonomous Province of Bolzano has made the information available for booking the Covid vaccine for the categories concerned in this phase of the vaccination plan a this web address . At the moment the reservation is active for people with more than 75 years old (more information on the categories here).
Calabria, which has adopted the booking platform of the Italian Post Office , began vaccinations for over 80s on February 22, according to time schedule of the region. Those entitled they get a call from their doctor general practitioner to make an appointment. Here more details .
Campania has organized itself with one web platform for booking . The form asks for the insertion of the tax code and health card number, then to provide e-mail and telephone contact details. From March 13, reservations are also possible for over 70 to this link.
On the site of the Emilia Romagna Region you will find all the information relating to reservations for priority categories in the anti-Covid vaccination plan. This is the program:
- from 1 March all persons aged 80 and over, born in 1941 and in previous years
- from March 15th people aged between 75 and 79 (those born in the years 1942, 1943, 1944, 1945 and 1946).
It is possible to book by going to the desks Cup, or in pharmacies with online Cup bookings through the Electronic health record, the Er Salute app and CupWeb . Otherwise calling to the numbers provided for in the Usl to which they belong for telephone booking.
Friuli Venezia Giulia
How it is read on the website of the Autonomous Region of Friuli Venezia Giulia, "From 10 February it is possible for all citizens who have reached the age of 80 to book vaccination against Covid-19, whose administration will begin on February 15th . Vaccination can be booked through Cup of the Health Authorities and the pharmacies , or through the Call center at the single number 0434 223522 ” . Phase 2 priority categories will be vaccinated based on vaccine availability. Vaccination for extremely vulnerable people and for those between 75 and 79 years old began on Wednesday 24 March (more information here).
All information on Covid vaccines , on who can book and how they can be consulted on site of the region. For the over eighty (born until 1941), in particular, reservations were open from 1 February (but registration for the school staff and some types of vulnerable patients ).
From 10 March online bookings are also open for other age groups, with this time scan and at this link . After the vintages from 1944 to 1951, starting from March 27 it will be possible to book the vaccine for those who are 68 and 69 years old (those born in 1953 and 1952).
There booking can be made online , or by calling the assistance number 06 164161841 . Here instead the Faq of the region on anti-Covid vaccines.
The Liguria Region has activated a site to manage reservations for anti-Covid-19 vaccines. At the moment it is possible to book if you fall into the following categories:
- people over 80 years old
- very vulnerable people under the age of 80
- people aged between 75 and 79 years
- school and university staff, police forces, judicial offices and civil protection.
Reservations can be made on the website, via the toll-free number 800 938 818 (from 8:00 to 18:00), at the Cup counters, the Asl, the hospitals, or le pharmacies carrying out Cup service.
From Monday 29 March it will also be possible to book for people aged between i 70 and i 74 years.
As indicated on the site dedicated to the emergency, in the Lombardy Region the over 80 they can call the toll-free number 800 894 545 , and from February 15th it is possible to join the vaccination campaign through this one online platform. The same system is also valid for Lombard citizens aged between 60 and 79 years residing in the municipalities declared ad high risk and therefore considered a priority. “Citizens who register their membership will be informed later by sms (or they will receive a call , if only the fixed number was provided) of the date, time and place where the vaccination will be performed " .
To summarize, one can vacicnare:
- those over 80 years old (including people born in 1941)
- those aged between 60 and 79 and residing in high-risk municipalities (for the province of Brescia: Capriolo, Iseo, Palazzolo sull’Oglio, Paratico, Pontoglio, Roccafranca, Rudiano, Urago d’Oglio for the province of Cremona: Soncino)
- the staff of state schools (teachers and non-teachers, substitutes, school managers)
- the staff of vocational training institutes and higher technical institutes
- school staff (teaching and non-teaching) of private schools
- the staff of the educational services for the infancy and the schools for the infancy
- the teaching and non-teaching staff of the Afam System.
At the moment it does not seem possible to book vaccination for those between 70 and 79 years old.
From 12 February on the portal of the Marche Region Health Authority, it is possible to book anti-Covid vaccination for citizens who are 80 years of age or older. The reservation goes through the Poste platform and the toll-free number 800.00.99.66 . At the moment it does not seem possible to book vaccination for those who have 70 and 79 years, but the regional councilor for health Filippo Saltamartini communicated with a post on Facebook that vaccination for this category will begin from April with the arrival of new supplies.
The procedures for joining the anti-Covid vaccination in Molise are illustrated in this Web page . There is a section dedicated to over eighty , which can therefore be booked online on the same platform or call 800 329 500 from landline or al 0865724242 from mobile. At the moment it does not seem possible to book vaccinations for those between 70 and 79 years old, but they are open instead for extremely vulnerable people and school staff.
Piedmont has begun to collect adhesions to the anti-Covid vaccination campaign for over 80s from February 15 through the general practitioners , who then must register the will of their clients on appropriate platform regional. The appointments are finalized by the ASL of competence and citizens also informed through sms or e-mail . Dosing began on February 21st. For the school and university staff Piedmontese, on the other hand, you must follow the instructions contained in this Web page . From 15 March the pre-accessions for people aged between 70 and 79, always on the same platform .
Apulian over 80s can book anti-Covid vaccination through the PugliaSalute website , in authorized pharmacies to the Farmacup service and through the Cup of its Asl. Here all the references . Al momento non sembra possibile prenotare la vaccinazione per chi invece ha tra i 70 e i 79 anni, ma da calendario dovrebbe diventare possibile da fine marzo.
La Sardegna ha pubblicato il proprio piano e il cronoprogramma della campagna vaccinale anti-Covid. Per gli over 80 che non sono residenti nelle strutture socio-sanitarie della regione la campagna parte il primo marzo per i nati fino al 1936 , e dal 15 marzo per i nati dal 1937 al 1941 . “ A partire dal primo marzo, verrà inviato un sms per invitare il cittadino a manifestare la volontà di aderire alla campagna vaccinale. Si procederà quindi a prenotare gli aderenti che saranno contattati dalle segreterie Cup per comunicare ad essi la data ed il luogo della somministrazione del vaccino. Per gli over 80 che non hanno avuto la possibilità di aderire o per coloro che hanno necessità della somministrazione a domicilio, saranno disponibili dal primo aprile ulteriori canali di contatto: sportelli Cup, chiamata diretta da parte delle segreterie Cup sulla base delle liste prenotazione telefonica tramite il numero unico 1533 ” .
Da cronoprogramma regionale , le vaccinazioni per le persone tra i 59 e i 79 anni inizieranno ad aprile per finire a giugno, cominciando dai più anziani.
La Sicilia ha aderito alla piattaforma online di Poste italiane , oltre che del portale informativo CostruireSalute.it . Gli ultraottantenni possono prenotare la vaccinazione compilando online la scheda di pre-adesione oppure chiamando al numero verde 800 009 966 . Lo stesso vale ora per chi ha tra i 70 e i 79 anni, in una sezione dedicata .
Come indicato sul sito della Regione, “a partire da metà febbraio le persone con più di 80 anni saranno contattate personalmente dal proprio medico di famiglia che comunicherà loro il giorno e il luogo della vaccinazione. Per chi è impossibilitato a muoversi la vaccinazione sarà effettuata al domicilio” .
Dal 10 marzo sono aperte le prenotazioni anche per le persone dai 76 ai 79 anni , nati nel 1941-42-43-44.
Per ulteriori informazioni è possibile consultare il portale prenotavaccino.sanita.toscana.it .
Per informazioni sulla vaccinazione anti-Covid nella Provincia autonoma di Trento è possibile consultare le Faq sul sito dedicato. Per gli over 80 la prenotazione va effettuata tramite Cup online . Prenotando la prima dose viene in automatico fissato l’appuntamento per il richiamo.
Dalle 23:00 of sabato 13 marzo possono prenotare anche le persone che hanno compiuto 75 anni , sempre sulla stessa piattaforma .
Sul portale della Regione Umbria si trovano le informazioni per la vaccinazione anti-Covid. Due le modalità di prenotazione: il portale web Cup Umbria oppure presso tutte le farmacie . Il numero per assistenza e informazioni è 800.192.835 . Non è ancora possibile prenotare la vaccinazione per chi invece ha tra i 70 e i 79 anni, ma la Regione ha concluso un accordo con i medici di medicina generale per procedere rapidamente non appena possibile.
Dal primo marzo la Valle d’Aosta ha avviato la campagna di vaccinazione di massa , pur rispettando le priorità stabilite dal piano nazionale. Sarà infatti la Usl a contattare la popolazione per raccogliere le adesioni. Tutte le informazioni sono reperibili sul sito anticovid.regione.vda.it e sul sito della Usl alla sezione Infovaccini . L’appuntamento dovrà poi essere confermato con le modalità indicate. Al momento sono partite le vaccinazioni per le persone tra i 70 e i 79 anni.
Il Veneto è in fase di completamento della fase 1.B del programma vaccinale, che comprende i nati fino al 1941, e della fase 2 dedicata ai soggetti estremamente vulnerabili indipendentemente dall’età e ai lavoratori dei servizi essenziali. Come si legge sul sito della Regione, “successivamente (o in contemporanea, in funzione della disponibilità del vaccino) si procederà con la chiamata dei soggetti di età compresa tra 79 ed i 55 anni, partendo con la chiamata della coorte dei 79enni (nati nel 1942) e proseguendo verso le coorti più giovani“.
La Regione ha scelto di procedere per contatto diretto che avverrà da parte delle Ulss competenti. Maggiori informazioni su modalità di convocazione e l’elenco delle sedi vaccinali sono disponibili a questo link.